Depression, Inflammation, and the Moderating Role of Metformin: Results From the Midlife in the United States Study and Sacramento Area Latino Study on Aging

Is age more than a number? Accounting for adult development and aging in the study of psychoneuroimmunology, stress, and health

Traditional stress-and-health models link stressors to their health consequences through a well-characterized cascade. Most of the research assumes that the stress-health sequence unfolds in the same way across adulthood, whether a person is 25 years old or 80. Taking a "developmental" or "lifespan" approach has been synonymous with studying the lasting health impacts of early life experiences. However, theories and evidence from adult development and geroscience suggest that stress-health dynamics evolve in important ways over the adult lifespan-from the stressors that we encounter, to the emotion regulation strategies that we use to confront challenges, to the psychosocial resources at our disposal, to the cellular milieu, and thus to the magnitude of stressors' biological and functional consequences. This critical review synthesizes theoretical perspectives and selected empirical literature on the social-emotional and biological dimensions of aging to promote an Integrative Model of Aging, Stress, and Health. Through this integration, the model illustrates how an interdisciplinary, developmental perspective can enrich our understanding of stress's consequences for health across adulthood. It also seeks to guide a new generation of research questions that confront aging with a multidimensional approach. The piece concludes with personal reflections on the foundational legacy of the author's mentor, Dr. Janice Kiecolt-Glaser.

New Directions in Geroscience: Integrating Social and Behavioral Drivers of Biological Aging

ABSTRACT

The "geroscience hypothesis" posits that slowing the physiological processes of aging would lead to delayed disease onset and longer healthspan and lifespan. This shift from a focus on solely treating existing disease to slowing the aging process is a shift toward prevention, including a focus on risk factors found in the social environment. Although geroscience traditionally has focused on the molecular and cellular drivers of biological aging, more fundamental causes of aging may be found in the social exposome-the complex array of human social environmental exposures that shape health and disease. The social exposome may interact with physiological processes to accelerate aging biology. In this commentary, we review the potential of these insights to shape the emerging field of translational geroscience. The articles in this special issue highlight how social stress and social determinants of health are associated with biomarkers of aging such as inflammation, epigenetic clocks, and telomeres, and spotlight promising interventions to mitigate stress-related inflammation. For geroscience to incorporate the social exposome into its translational agenda, studies are needed that elucidate and quantify the effects of social exposures on aging and that consider social exposures as intervention targets. The life course perspective allows us to measure both exposures and aging biology over time including sensitive periods of development and major social transitions. In addition, given rapid changes in the measurement of aging biology, which include machine learning techniques, multisystem phenotypes of aging are being developed to better reflect whole body aging, replacing reliance on single system biomarkers. In this expanded and more integrated field of translational geroscience, strategies targeting factors in the social exposome hold promise for achieving aging health equity and extending healthy longevity.

Possible role of metformin as an antidepressant in diabetes

OBJECTIVE

Metformin (MET) is a drug used in the treatment of type 2 diabetes due to its insulin receptor sensitizing properties and anti-hepatic gluconeogenesis effect. One of the comorbidities in diabetes is the depression. This review aimed at summarizing the results of the available MET, depression and diabetes studies to clarify the possible role of MET in the depression during diabetes.

METHODS

A bibliographic search on PubMed, Embase, PsycINFO, Web of Science, Cochrane Central for studies referring to MET, depression and diabetes.

RESULTS

Several studies have associated depression to the chronic inflammation that characterizes diabetes. Additionally MET is an anti-inflammatory molecule that generally acts by activating AMPK and inhibiting the NF-kB factor. In the context of diabetes, MET can act directly as an anti-inflammatory drug as well as inhibiting other pro-inflammatory molecules. In this regard, MET may inhibit the pro-inflammatory effects of angiotensin II. By facilitating the action of insulin and reducing hepatic gluconeogenesis, MET reduces circulating glucose levels, decreasing the formation of advanced glycation end products and therefore inflammation. During diabetes, the gut microbiota and the permeability of the intestinal barrier are altered, causing high levels of circulating lipopolysaccharides (LPS), which induce inflammation. MET can normalize the microbiota and the intestinal barrier permeability reducing the levels of LPS and inflammation. Clinical and experimental studies show the anti-depressant effect of MET mediated by different mechanisms both at the peripheral level and in the central nervous system.

CONCLUSION

Therefore, MET as an anti-inflammatory drug can decrease symptoms of depression and represents a therapeutic approach to improve the psychological state of patients with diabetes. Additionally, insulin also has an anti-inflammatory effect that could act together with MET.